Wednesday, July 19, 2017

Gilead Vosevi’s (Sofosbuvir/Velpatasvir/Voxilaprevir) price at $24,920 per bottle

Investment Commentary

Gilead gets its go-ahead for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble?
by Carly Helfand |
Jul 19, 2017 11:15am 
Gilead has set Vosevi’s price at $24,920 per bottle, putting it “at parity” with Epclusa at $74,760 for the 12-week course, Porges wrote in a note to clients. “Effectively Gilead is giving the third component of Vosevi free of charge to maintain the price point of their 12-week treatment course,” he said, noting that “ given this label and position in the treatment hierarchy, Gilead could have priced Vosevi higher and probably not lost significant share.”
Continue reading ..

Investment Commentary
How AbbVie Could Hammer Gilead's Hepatitis C Franchise 
  • 7/19/2017
  • Meanwhile, AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients.Gilead is pricing its triple-pill, which will be branded as Vosevi, at $24,920 per bottle. At one bottle per month, that runs up to a 12-week price of about $75,000. That is less costly than Gilead's Harvoni and Sovaldi, but more expensive than Zepatier
     Continue reading.....

    Recommended Reading
    Gilead's VoseviTM (Sofosbuvir/Velpatasvir/Voxilaprevir) FDA Approved for Re-Treatment of Adults with HCV

    No comments:

    Post a Comment